VIRPAX PHARMACEUTICALS INC (VRPX) Stock News
NASDAQ:VRPX - Nasdaq - US9282512063 - Common Stock - Currency: USD
VRPX Latest News, Press Relases and Analysis
Unusual volume stocks in Tuesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
Wondering what's happening in today's pre-market session?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
What's going on in today's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Check out the stocks that are attracting the most attention and driving market activity.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Unusual volume stocks in Friday's session
Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.
Mentions: PCRX
Friday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.
Top movers in Friday's pre-market session
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Get insights into the top gainers and losers of Thursday's after-hours session.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
